| Literature DB >> 29422614 |
Floris Vanommeslaeghe1, Wim Van Biesen2, Manuel Dierick3, Matthieu Boone3, Annemieke Dhondt2, Sunny Eloot2.
Abstract
A novel technique based on micro-CT scanning is developed to quantify coagulation in fibers of hemodialyzers. This objectivation is needed to allow accurate assessment of thrombogenicity of dialyzers used during hemodialysis, for example when comparing different strategies to avoid coagulation and/or fiber blocking. The protocol allowed imaging at a resolution of 25 µm, making it possible to count the open, non-coagulated fibers in a non-invasive way. In 3 fresh, non-used FX600 hemodialyzers, patent fiber counts were extremely consistent (10748 ± 2). To illustrate the potential of this technique, different dialysis parameters currently used as surrogates for fiber blocking were evaluated during 20 hemodialysis sessions. After dialysis, the FX600 dialyzers were visually scored for clotting, dried and subsequently weighed and scanned. The number of patent fibers (10003 [8763,10330], range 534-10692) did not correlate with any of the recorded surrogate parameters. Micro-CT scanning is a feasible, objective, non-invasive, accurate and reproducible tool for quantification of the degree of fiber blocking in a hemodialyzer after use, making it a potential gold standard for use in studies on fiber blocking during renal replacement therapies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29422614 PMCID: PMC5805764 DOI: 10.1038/s41598-018-20898-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Representative CT images of dialyzer cross-sections (reference slice) showing different levels of coagulation.
Number of open fibers as counted in the different scanned dialyzers (percentage of difference in open fibers versus those in the reference slice, and related to the total number of fibers).
| Dialyzer | Reference slice, | 2.5 mm from reference slice, threshold 70% | Reference slice, threshold 60% | Reference slice, threshold 80% |
|---|---|---|---|---|
| NON-USED DIALYZERS | ||||
| Blanco 1 | 10746 | 10748 (0) | 10749 (0) | 10743 (0) |
| Blanco 2 | 10750 | 10751 (0) | 10751 (0) | 10749 (0) |
| Blanco 3 | 10749 | 10749 (0) | 10751 (0) | 10745 (0) |
| Mean ± SD | 10748 ± 2 | 10749 ± 2 | 10751 ± 1 | 10745 ± 3 |
| USED DIALYZERS | ||||
| 1 | 5443 | 5497 (0.5) | 5478 (0.3) | 5391 (0.5) |
| 2 | 7632 | 8290 (6.1) | 7645 (0.1) | 7615 (0.2) |
| 3 | 10328 | 10477 (1.4) | 10329 (0) | 10321 (0.1) |
| 4 | 10246 | 10305 (0.5) | 10256 (0.1) | 10215 (0.3) |
| 5 | 10335 | 10368 (0.3) | 10336 (0) | 10323 (0.1) |
| 6 | 10228 | 10391 (1.5) | 10232 (0) | 10219 (0.1) |
| 7 | 8327 | 8335 (0.1) | 8335 (0.1) | 8258 (0.6) |
| 8 | 534 | 558 (0.2) | 544 (0.1) | 352 (1.7) |
| 9 | 10041 | 10134 (0.9) | 10043 (0) | 10030 (0.1) |
| 10 | 9451 | 9118 (3.1) | 9461 (0.1) | 9442 (0.1) |
| 11 | 10234 | 10293 (0.5) | 10283 (0.5) | 10106 (1.2) |
| 12 | 6066 | 6323 (2.5) | 6093 (0.4) | 5998 (0.5) |
| 13 | 10692 | 10688 (0) | 10695 (0) | 10682 (0.1) |
| 14 | 10587 | 10656 (0.6) | 10588 (0) | 10578 (0.1) |
| 15 | 8908 | 9330 (3.9) | 8968 (0.6) | 8800 (1.0) |
| 16 | 10351 | 10419 (0.6) | 10364 (0.1) | 10299 (0.5) |
| 17 | 8994 | 8406 (5.5) | 9019 (0.2) | 8966 (0.3) |
| 18 | 10465 | 10535 (0.7) | 10467 (0) | 10451 (0.1) |
| 19 | 9965 | 9903 (0.6) | 9974 (0.1) | 9936 (0.3) |
| 20 | 9752 | 9791 (0.4) | 9764 (0.1) | 9707 (0.4) |
| Median [IQR] | 10003 [8763;10330] | 10019 [8388;10398] | 10009 [8810;10331] | 9983 [8665;10305] |
Absolute values as well as regression coefficients (R²) of the associations of the number of open fibers with the post dialysis measurements and scorings, and with the interdialytic changes in registered machine parameters in the 20 dialysis sessions.
| Dialyzer | #fibers | dialyzer dry mass (g) | visual scoring dialyzer | visual scoring venous chamber | Rinse back volume (mL) | arterial pressure pre-post (mmHg) | venous pressure pre-post (mmHg) | TMP | BVM | OCM |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 5443 | 224.0 | 4 | 3 | 220 | 25 | −5 | 160 | 7 | 28 |
| 2 | 7632 | 222.5 | 3 | 2 | 280 | 0 | −45 | 80 | 9 | 31 |
| 3 | 10328 | 142.0 | 1 | 1 | 280 | 10 | 20 | 30 | 4 | 18 |
| 4 | 10246 | 176.0 | 2 | 1 | 270 | 10 | −105 | 55 | 11 | 19 |
| 5 | 10335 | 187.5 | 2 | 2 | 270 | 30 | 15 | 20 | 6 | 6 |
| 6 | 10228 | 187.5 | 2 | 2 | 270 | −25 | 0 | 65 | 6 | 5 |
| 7 | 8327 | 202.5 | 3 | 2 | 260 | 25 | 10 | 35 | 5 | 4 |
| 8 | 534 | 283.0 | 4 | 3 | 360 | 60 | −35 | 75 | 20 | 66 |
| 9 | 10041 | 171.0 | 1 | 1 | 260 | 55 | −20 | 10 | 12 | −9 |
| 10 | 9451 | 212.0 | 1 | 1 | 270 | 15 | 40 | 65 | 10 | 17 |
| 11 | 10234 | 192.0 | 2 | 2 | 260 | 65 | 30 | 60 | 9 | 13 |
| 12 | 6066 | 240.0 | 3 | 3 | 270 | −5 | 75 | 15 | 3 | 6 |
| 13 | 10692 | 157.5 | 1 | 2 | 270 | 15 | 5 | 25 | 7 | 0 |
| 14 | 10587 | 137.0 | 2 | 2 | 290 | 10 | 0 | 50 | 5 | 19 |
| 15 | 8921 | 158.0 | 4 | 2 | 260 | −10 | 5 | 110 | 5 | 15 |
| 16 | 10351 | 202.0 | 2 | 1 | 310 | −35 | 5 | 5 | −2 | 2 |
| 17 | 8998 | 209.0 | 4 | 1 | 260 | −10 | 15 | 125 | 6 | 8 |
| 18 | 10465 | 167.0 | 2 | 2 | 270 | 20 | 20 | 70 | 13 | 10 |
| 19 | 9965 | 217.0 | 3 | 3 | 250 | 65 | 45 | 35 | 8 | 92 |
| 20 | 9752 | 218.5 | 3 | 1 | 260 | 35 | 20 | 35 | 13 | 49 |
| R² (with #fibers): |
|
|
|
|
|
|
|
|
| |
*p < 0.05; #number; TMP: transmembrane pressure; BVM: blood volume monitoring; OCM: online clearance monitoring.
Figure 2Associations between the number of fibers and a selection of different registered parameters: dialyzer dry mass (panel A), visual scoring of dialyzer (panel B), post minus pre dialysis TMP (panel C), and pre minus post dialysis OCM (panel D).
Patient characteristics and baseline laboratory data.
| Median [Q1; Q3] and (min; max) or n (%) | |
|---|---|
| Cause of ESRD no. (%) | |
| Diabetic/hypertensive nephropathy | 7 (35%) |
| Post-Renal Causes | 3 (15%) |
| Glomerulonephritis | 4 (20%) |
| Others | 6 (30%) |
| Co-existing illnesses no. (%) | |
| Smoking | 2 (10%) |
| History of cancer | 7 (35%) |
| Diabetes | 6 (30%) |
| Thromboembolic Venous Disease | 5 (25%) |
| Antithrombic therapy—no. (%) | |
| Aspirine (monotherapy) | 11 (55%) |
| Clopidogrel (monotherapy) | 0 |
| Aspirine and Clopidogrel | 1 (5%) |
| Vitamin K antagonist | 3 (15%) |
| Dialysis LMWH anticoagulation | |
| No anticoagulation | 1 (5%) |
| Enoxaparin 20 mg | 1 (5%) |
| Enoxaparin 40 mg | 4 (20%) |
| Enoxaparin 60 mg | 4 (20%) |
| Tinzaparin 2500 U | 2 (10%) |
| Tinzaparin 3500 U | 5 (25%) |
| Tinzaparin 4500 U | 3 (15%) |
| Clotting Parameters (mean + −SD) | |
| Hemoglobin, g/dl | 9.8 [8.7–11.8] (7.9–13.5) |
| Hematocrit, % | 31.0 [27.7–36.0] (22.8–41.6) |
| Platelets, x 10E3/µL | 179 [115–255] (43–431) |
| Prothrombin time (PT) | 86 [69–102] (21–115) |
| International Normalized Ratio (INR) | 1.1 [1.0–1.3] (0.9–3.6) |
| Access | |
| Arteriovenous fistula | 7 (35%) |
| Permanent dialysis catheter | 13 (65%) |
Visual clotting scores.
| Clotting score dialyzer | Number of dialyzers (%) | |
|---|---|---|
| 1 | Clean filter | 4 (20) |
| 2 | Few dark red fibers | 7 (35) |
| 3 | <50% dark red fibers | 5 (25) |
| 4 | >50% dark red fibers | 4 (20) |
| Venous chamber scoring | ||
| 1 | no detectable clotting | 7 (35) |
| 2 | minimal clot formation | 9 (45) |
| 3 | clots up to 5 cm but dialysis still possible | 4 (20) |
| 4 | complete occlusion of the air trap | 0 (0) |
Figure 3CT images of cross-sections in the same used dialyzer halfway the dialyzer (left panel) and at the central cross-section in the outlet potting (right panel). Central fibers are open and peripheral fibers are blocked. Sections in the potting offer optimal visualization of air inflated open fibers, appearing as black dots.
Figure 4CT image of cross-section (panel A). Optimization of image brightness and selection of the region of interest (ROI) bordering the entire fiber bundle (panel B). Zoomed inset of counted fibers (panel C).